Vaccine candidate against COVID-19
Pharmaceutical compound
| Part of a series on the |
| COVID-19 pandemic |
|---|
 |
|
|
Medical response |
|
 COVID-19 portal |
AKS-452 is a COVID-19 vaccine candidate developed by Akston Biosciences.[2][3]
References
- ^ "Patent Landscape Report COVID-19-related vaccines and therapeutics" (PDF).
- ^ "Anti-COVID19 AKS-452 – ACT Study (ACT)". ClinicalTrials.gov. 23 December 2020. NCT04681092. Retrieved 21 March 2021.
- ^ "A study to assess the safety and immunogenicity of Anti-COVID-19 AKS-452 vaccine for SARS-Сov-2 infection in Indian healthy subjects". ctri.nic.in. 11 October 2021. CTRI/2021/10/037269. Retrieved 11 October 2021.
Scholia has a profile for AKS-452 (Q110269780).
| Development | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Classes | |||||||||||
| Administration | |||||||||||
| Vaccines |
| ||||||||||
| Inventors/ researchers | |||||||||||
| Controversy | |||||||||||
| Related | |||||||||||
| |||||||||||
Allikas: http://en.wikipedia.org/wiki/AKS-452
You must be logged in to post a comment.